EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Causal Exposure‐Response Analysis: Estimands, Time‐Varying Confounding, and the Parametric g‐Formula

Nathan Braniff

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Nathan Braniff. Beteiligte Einrichtung: Pharmacometrics and Systems Pharmacology, Pfizer Inc, San Diego, California, USA. Hauptthemen laut MEDLINE: Dose-Response Relationship, Drug. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exposure‐response (ER) analysis often informs dose selection in clinical drug development, but the underlying causal assumptions are rarely made explicit. Exposure metrics commonly used in practice can have limitations: time‐to‐event metrics are outcome‐dependent and can be causally incoherent; steady‐state metrics can introduce immortal‐time bias; and early metrics, while defensible, require unstated assumptions about later exposure or must be interpreted narrowly. Beyond metric selection, challenges persist even with ideal early or time‐varying exposure metrics, as dose randomization protects against confounding only for the component of exposure variability driven by the assigned dose. On‐treatment clinical variables can affect both exposure and response, inducing time‐varying confounding that neither randomization, baseline adjustment, nor naive time‐varying covariate adjustment can address. In this work, a directed acyclic graph (DAG) is used to formalize the causal structure and define the average causal exposure‐response curve (ACERC) as the target estimand for ER analysis under time‐varying confounding. The parametric g‐formula is adapted to target this causal estimand and required assumptions are stated explicitly, including key consistency and no‐multiple‐versions‐of‐treatment (NMVT) assumptions, with implications for defining exposure metrics. Population pharmacokinetic (popPK) modeling serves an important role beyond computing exposure metrics, partially addressing the no‐measurement‐error assumption and enabling g‐formula implementation via existing software. Two oncology‐motivated simulation scenarios of dose‐mediated and PK‐mediated confounding illustrate the approach. A simulation study shows the g‐formula recovers causal ER estimates where standard methods are inaccurate under the specified time‐varying confounding. The two‐step workflow combining popPK modeling with existing g‐formula software is presented as a practical template for further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dose-Response Relationship, DrugHumansComputer SimulationConfounding Factors, EpidemiologicTime Factors

Autor:innen und Institutionen

  • Pharmacometrics and Systems Pharmacology, Pfizer Inc, San Diego, California, USA.

Zitieren

APA

Braniff, N. (2026). Causal Exposure‐Response Analysis: Estimands, Time‐Varying Confounding, and the Parametric g‐Formula. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70346

Vancouver

Braniff N. Causal Exposure‐Response Analysis: Estimands, Time‐Varying Confounding, and the Parametric g‐Formula. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70346

BibTeX
@article{Braniff2026,
  author = {Braniff, Nathan},
  title = {Causal Exposure‐Response Analysis: Estimands, Time‐Varying Confounding, and the Parametric g‐Formula},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70346}
}
Kostenlos starten →